Delage, J.A.; Faivre-Chauvet, A.; Barbet, J.; Fierle, J.K.; Schaefer, N.; Coukos, G.; Viertl, D.; Dunn, S.M.; Gnesin, S.; Prior, J.O.
Impact of DOTA Conjugation on Pharmacokinetics and Immunoreactivity of [177Lu]Lu-1C1m-Fc, an Anti TEM-1 Fusion Protein Antibody in a TEM-1 Positive Tumor Mouse Model. Pharmaceutics 2021, 13, 96.
https://doi.org/10.3390/pharmaceutics13010096
AMA Style
Delage JA, Faivre-Chauvet A, Barbet J, Fierle JK, Schaefer N, Coukos G, Viertl D, Dunn SM, Gnesin S, Prior JO.
Impact of DOTA Conjugation on Pharmacokinetics and Immunoreactivity of [177Lu]Lu-1C1m-Fc, an Anti TEM-1 Fusion Protein Antibody in a TEM-1 Positive Tumor Mouse Model. Pharmaceutics. 2021; 13(1):96.
https://doi.org/10.3390/pharmaceutics13010096
Chicago/Turabian Style
Delage, Judith Anna, Alain Faivre-Chauvet, Jacques Barbet, Julie Katrin Fierle, Niklaus Schaefer, George Coukos, David Viertl, Steven Mark Dunn, Silvano Gnesin, and John O. Prior.
2021. "Impact of DOTA Conjugation on Pharmacokinetics and Immunoreactivity of [177Lu]Lu-1C1m-Fc, an Anti TEM-1 Fusion Protein Antibody in a TEM-1 Positive Tumor Mouse Model" Pharmaceutics 13, no. 1: 96.
https://doi.org/10.3390/pharmaceutics13010096
APA Style
Delage, J. A., Faivre-Chauvet, A., Barbet, J., Fierle, J. K., Schaefer, N., Coukos, G., Viertl, D., Dunn, S. M., Gnesin, S., & Prior, J. O.
(2021). Impact of DOTA Conjugation on Pharmacokinetics and Immunoreactivity of [177Lu]Lu-1C1m-Fc, an Anti TEM-1 Fusion Protein Antibody in a TEM-1 Positive Tumor Mouse Model. Pharmaceutics, 13(1), 96.
https://doi.org/10.3390/pharmaceutics13010096